Ca-4-methyl-2-oxo-valerate (α-ketoanalogue to leucine, Ca salt) 101 mg, Ca-3-methyl-2-oxo-butyrate (α-ketoanalogue to valine, Ca salt) 86 mg, Ca-2-oxo-3-phenylpropionate (α-ketoanalogue to phenylalanine, Ca salt) 68 mg, Ca-3-methyl-2-oxo-valerate (α-ketoanalogue to isoleucine, Ca salt) 67 mg, Ca-DL-2-hydroxy-4-(methylthio) butyrate (α-ketoanalogue to methionine, Ca salt) 59 mg, L-lysine acetate 105 mg, L-threonine 53 mg, L-histidine 38 mg, L-tyrosine 30 mg, L-tryptophan 23 mg
Indications/Uses
Prevention & treatment of damages due to faulty or deficient protein metabolism in CKD in connection w/ limited dietary protein intake of ≤40 g daily in adults, usually in patients w/ GFR <25 mL/min.
Risk of pathological increases of serum Ca level or intensification w/ Ca-containing medicaments eg, acetolyte. Reduce administration of Al hydroxide as uremic symptoms improve during therapy. Interfered absorption by drugs that form sparingly soluble compd w/ Ca eg, tetracyclines.
Sign Out
